AzTrials
AzTrials

Heart FailureNCT06007079

Clinical Data Collection Study Using CPM System

A study testing CPM Device in people with Heart Failure, run by Analog Device, Inc. at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study will assess the deployment of the ADI CPM System in a home setting and determine the interoperability of the CPM System within existing care pathways for HF patients. Clinicians will be blinded to CPM generated data and acquired physiologic data will not be used in clinical decision-making. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure
What is being tested?
CPM Device
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2 participants
Where
1 siteUnited States
Study dates
6 Dec 2023to 26 Oct 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • Under 18 years of age
  • Patients with severe COPD (GOLD stage III or IV)
  • Chronic Kidney Disease (eGFR < 20)
  • Limited mobility preventing application of device
  • Cognitive impairments that would limit the application and proper use of the device
  • Skin allergies or skin sensitivities to silicone-based adhesives
Show all 12Show fewer
  • Pregnancy
  • Skin breakdown on the left chest or breast area
  • Not willing to shave chest hair if needed to apply device
  • Patients on chronic inotropic therapy
  • Patients with any condition that might limit the survival to less than 1 year as assessed by the investigator
  • No cellular coverage (Patient's Home)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Columbia University Medical Center

    New York, New York, 10032

Other trials in United States

About this study

Official title: Clinical Data Collection Study Using CardioPulmonary Management System in Patients With Chronic Heart Failure

This study will assess the deployment of the ADI CPM System in a home setting and determine the interoperability of the CPM System within existing care pathways for HF patients. Clinicians will be blinded to CPM generated data and acquired physiologic data will not be used in clinical decision-making. After conclusion of this phase, a retrospective review of CPM System-acquired data will be compared with changes in treatment and HF events. This retrospective review will inform the subsequent design of the interventional study that is planned. Study participation for each patient will last for six months inclusive of 5 months of daily CPM monitoring followed by 30 days of observation for HF-related events. The additional 30 days of medical record observation is intended to capture any events that might correspond to predictions made during the final weeks of CPM monitoring.

Read the detailed description

The current investigation is designed to be an observational study of the feasibility of using the CPM system. Its goal is to familiarize the study team with the CPM system, uncover potential challenges in its deployment, assess its predictive ability, and ultimately define clinical protocols to react to CPM generated information. The next phase of investigation will be a pilot study of the efficacy of using the CPM system to prevent heart failure hospitalizations.

The patient will use the CPM device once daily during the first 5 months of the study. Patient records will be retrospectively reviewed over those 5 months plus an additional 30 days following the final CPM measurement to assess for any CHF-related events.

Baseline/Initial Visit (Visit 1):

At this visit, the start of the study, the information described in the "Baseline Assessments" section will be collected. The study will be re-described to the participant. The study team will then set up the device for the individual patient by making adjustments (as needed) to address patient specific anatomy, ensuring that the sensors are all contacting the appropriate chest areas, and confirming the measurements on the CPM Web application. The patient will be shown how to apply and replace the adhesive on the device, how to position the device, how to take a measurement with the device, and how to store the device on the Base Station. The trained provider will then register the baseline reading for the CPM device using the CPM Mobile App. Informational material about using the device, refreshing adhesives, and interpreting device LEDs and chimes will be provided to each patient. Each patient will be reminded to take a measurement with their CPM at the same time each day (preferably when they first wake up) and instructed to follow the medical regimen prescribed by their physician.

Between Visits:

Between visits, caregivers will not have any access to the data being collected on the CPM System. They should perform their usual standard of care on these patients. Participants will receive one call from the study team after 1 week of monitoring to check in about the progress of the study (i.e. if protocols are being followed correctly, if the CPM device is working properly, and if adherence is satisfactory). If the participant is found to have problems with the device, a follow up at week 2 can be scheduled. The check-in conversation topics should focus on any ease of use issues and address any technical barriers impacting compliance.

Follow-up Visit (Visit 2):

On this visit, which will take place at the end of the 5 months, the study team will make arrangements for the patient to return to the office for a check-up and return the device (the same tests as described in the "physical examination" section). Patients will also be asked about their perception on "ease of use", impact on day to day activities, and overall satisfaction with the CPM system. Thirty days following the last measurement the study team, will review the patients records for all HF related events and treatment changes. Study protocol will also include a phone call to the patient to inquire if they had any heart failure events during this time.

Post-Monitoring (Data review):

After the completion of the monitoring, the study team will analyze the de-identified data from the CPM system and correlate it with clinical events obtained from patients and their medical records. Threshold events flagged in the CPM data will then be compared to clinical data to determine the CPM's performance characteristics (sensitivity, specificity, PPV, NPV and AUC ROC), and median prediction time for HF events.

Conditions
Heart Failure
Being tested
CPM Device
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CPM DeviceDevice

    Wearable monitor

Study groups in NCT06007079
Study groupRoleWhat they receive
Device UseExperimentalPatients will be given the CPM device to take home and use once daily
Receives: Device: CPM Device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Record number of heart failure events

    A HF hospitalization is defined as any unplanned visit to a hospital, Emergency Department or Observation unit with a length of stay of at least 24 hours AND treatment with intravenous diuretics.

    Worsening heart failure is defined as having at least one sign or symptom of congestion including but not limited to: worsening dyspnea, orthopnea, PND, JVD, S3 gallop, pulmonary crackles, ascites or edema.

    Urgent treatment is defined as any use of intravenous diuretic therapy or an increased diuretic dosage (at least 2x baseline dose) and/or additional class of diuretics.

    Measured: 5 months

  2. Sensitivity

    Measuring the sensitivity of each parameter with respect to the ability to predict a CHF event. Sensitivity is defined as TP/(TP+FN) = True Positive/(True Positive+False Negative)

    Measured: 6 months

  3. Specificity

    Measuring the specificity of each parameter with respect to the ability to predict a CHF event. Specificity is defined as TN/(TN+FP) = True Negative/(True Negative+False Positive)

    Measured: 6 months

Secondary outcomes (2)
  1. Patient compliance

    Percentage of days that patient completes a recording.

    Measured: 5 months

  2. Data quality

    Measuring valid data available (valid days of measurement / total number of measurements)

    Measured: 5 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Aug 2023
  2. Study start6 Dec 2023
  3. Primary completion24 Oct 2024
  4. Study completion26 Oct 2024

Why it stopped: Terminated due to operational considerations

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
2 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06007079
Sponsor's protocol ID
ADI-NYP
Status last verified
Aug 2026
First submitted
18 Aug 2023
Last updated
19 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing CPM Device in people with Heart Failure, run by Analog Device, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Terminated due to operational considerations). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Record number of heart failure events (time frame: 5 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Data Collection Study Using CPM System | AzTrials